Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0YWAHM
ADC Name	DS-6000
Synonyms	DS 6000; DS6000; DS-6000a Click to Show/Hide
Organization	Daiichi Sankyo Co., Ltd.
Drug Status	Phase 1
Indication	In total 4 Indication(s) Epithelial ovarian cancer [ICD11:2B5D] Phase 1 Kidney cancer [ICD11:2C90-2C91] Phase 1 Ovarian cancer [ICD11:2C73] Phase 1 Renal cell carcinoma [ICD11:2C90] Phase 1
Drug-to-Antibody Ratio	8
Structure
	3D MOL	2D MOL
Antibody Name	Undisclosed
Antigen Name	Cadherin-6 (CDH6)		Antigen Info
Payload Name	DX-8951 derivative (DXd)		Payload Info
Therapeutic Target	DNA topoisomerase 1 (TOP1)		Target Info
Linker Name	Mc-Gly-Gly-Phe-Gly		Linker Info
Puchem SID	355207085

General Information of The Activity Data Related to This ADC

Identified from the Human Clinical Data

Click To Hide/Show 1 Activity Data Related to This Level

Standard Type	NCT Number	Clinical Status	Clinical Trial Description
Objective Response Rate (ORR)	NCT04707248	Phase 1	Phase 1, two-part, multi-center, first-in-human study of DS-6000A in subjects with advanced renal cell carcinoma and ovarian tumors.

Full List of Activity Data of This Antibody-drug Conjugate

Identified from the Human Clinical Data

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Objective Response Rate (ORR)	13.30% (all)
Patients Enrolled	Patients with advanced renal cell carcinoma or ovarian cancer. Patients had received a median of 4 prior systemic therapy.
Administration Dosage	First dose was 1.60 mg/kg followed by 3.20, 4.80, 6.40, 8.00, and 9.60 mg/kg every 3 weeks.
*Related Clinical Trial*
NCT Number	NCT04707248	Clinical Status	Phase 1
Clinical Description	Phase 1, two-part, multi-center, first-in-human study of DS-6000A in subjects with advanced renal cell carcinoma and ovarian tumors.

References

Ref 1	Phase I, two-part, multicenter, first-in-human (FIH) study of DS-6000a in subjects with advanced renal cell carcinoma (RCC) and ovarian tumors (OVC). J Clin Oncol. 2022 40:16_suppl, 3002-3002.